Factorial design for randomized clinical trials [6]

Annals of Oncology

Volumn 17, Issue 10, 2006, Pages 1607-1608

  Bria, Emilio ^a   Di Maio, M ^b   Nistico C ^a   Cuppone, F ^a   Terzoli, E ^a   Cognetti, F ^a   Giannarelli, D ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b National Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; DOCETAXEL; PACLITAXEL;

ADVANCED CANCER; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; FACTORIAL DESIGN; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; PRIORITY JOURNAL; RANDOMIZATION; STATISTICAL ANALYSIS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 33749635144     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl106     Document Type: Article

References (9)

1. Green MC, Buzdar AU, Smith T et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with once-every-3- weeks paclitaxel. J Clin Oncol 2005; 23: 5983-5992.
2. Seidman A. 'Will Weekly Work?' Seems to be so.... J Clin Oncol 2005; 23: 5873-5874.
3. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup trial c9741/Cancer and Leukemia Group B trial 9741. J Clin Oncol 2003; 21: 1431-1439.
4. Sparano JA, Wang M, Martino S et al. Phase III study of doxorubicincyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: Results of North American Breast Cancer Intergroup Trial E1199. Proceedings San Antonio Breast Cancer Symposium 2005.
5. Seidman AD, Berry D, Cirrincione C et al. Phase III study of weekly paclitaxel via 1-hour infusion versus standard 3h infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2 positive MBC and randomized for trastuzumab in HER2 normal MBC. Proc Am Soc Clin Oncol 2004; 22: 6s (Abstr 512).
6. Winer EP, Berry DA, Woolf S et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and leukemia group B trial 9342. J Clin Oncol 2004; 22: 2061-2068.
7. Jones SE, Erban J, Overmoyer B et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23: 5542-5551.
8. Taghian AG, Abi-Raad R, Assaad SI et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: Clinical implications. J Clin Oncol 2005; 23: 1951-1961.
9. Pasquier E, Honore S, Pourroy B et al. Anti-angiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65: 2433-2440.